Adaptimmune Therapeutics PLC (ADAPY)

PriceLoading quote

Financial charts

Revenue

Net income

Free cash flow

Total cash / debt

CashTotal debt

Financial statements

11 annual periodsNewest to oldest
20242023202220212020201920182017201620152014
Revenue$178.0M$60.3M$27.1M$6.1M$4.0M$1.1M$59.5M$37.8M$14.2M$9.9M$825,000
Research & development$149.1M$126.5M$127.7M$111.1M$91.6M$97.5M$98.3M$87.4M$63.8M$24.1M$9.6M
Operating income−$68.8M−$139.7M−$164.0M−$162.2M−$133.4M−$139.8M−$82.4M−$80.7M−$72.8M−$24.6M−$11.5M
EBITDAderived−$57.5M−$129.9M−$157.9M−$155.7M−$125.8M−$131.8M−$74.6M−$75.2M−$69.5M−$23.9M−$11.3M
Net income−$70.8M−$113.9M−$165.5M−$158.1M−$130.1M−$137.2M−$95.5M−$70.1M−$71.6M−$22.1M−$11.6M
Basic EPSper diluted share-$0.05-$0.09-$0.17-$0.17-$0.15-$0.22-$0.16-$0.13-$0.17-$0.17-$0.08
Diluted EPSper diluted share-$0.05-$0.09-$0.17-$0.17-$0.15-$0.22-$0.16-$0.13-$0.17-$0.17-$0.08

Insider buys & sells

Jul 1, 2024Jun 30, 2026
Buys0$0.00 disclosed value
Sells (SEC code S)24$7.05M disclosed value
24 recent transactions
TransactionInsiderTypeSharesPriceValueOwned after
Sep 2, 2025Form 4Wood GavinChief Financial OfficerSellOrdinary Shares with a nominal value of GBP0.001 per share96.0K$0.01$960.000
Aug 28, 2025Form 4Bertrand William C JRChief Operating OfficerSellOrdinary Shares with a nominal value of GBP0.001 per share207.0K$0.01$2.1K986.4K
Aug 18, 2025Form 4Behbahani AliDirectorSellOrdinary Shares with a nominal value of 0.001 GBP per share · indirect14.67M$0.01$146.7K0
Aug 15, 2025Form 4Behbahani AliDirectorSellOrdinary Shares with a nominal value of 0.001 GBP per share · indirect4.83M$0.01$48.3K14.67M
Jul 30, 2025Form 4EcoR1 Capital, LLCTenPercentOwnerSellOrdinary Shares · indirect27.43M$0.10$2.74M100.37M